Valproic acid-d6

Valproic acid-d6 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

Product Specifications

CAS Number

[87745-18-4]

Product Name Alternative

VPA-d6; 2-Propylpentanoic acid-d6

UNSPSC

12352211

Hazard Statement

H302, H315, H318

Target

Autophagy; Endogenous Metabolite; HDAC; HIV; Mitophagy; Notch

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; Neuronal Signaling; Stem Cell/Wnt

Field of Research

Cancer

Purity

99.83

Solubility

DMSO : 100mg/mL (ultrasonic)

Smiles

[2H]C([2H])([2H])CCC(C(O)=O)CCC([2H])([2H])[2H]

Molecular Formula

C8H10D6O2

Molecular Weight

150.25

Precautions

H302, H315, H318

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Valproic acid, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001 Sep 28;276 (39) :36734-41.|[3]Zhang ZH, et al. Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi 1 leukemia cells. Mol Med Rep. 2013 Nov 28.|[4]Platta CS, et al. Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res. 2008 Jul;148 (1) :31-7.|[5]Cohen OS, et al. Acute prenatal exposure to a moderate dose of valproic acid increases social behavior and alters gene expression in rats. Int J Dev Neurosci. 2013 Dec;31 (8) :740-50.|[6]Han BR, et al. Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. Oncol Rep. 2013 Dec;30 (6) :2999-3005.|[7]Avery LB, et al. Valproic Acid Is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice. Mol Pharmacol. 2014 Jan;85 (1) :1-10.